For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/whos-at-risk-for-tardive-dyskinesia-9044

Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD.

Summary
Tardive Dyskinesia (TD) exerts a profound negative impact across a patient’s life, including physical and cognitive domains and psychosocial functioning. This affects quality of life (QoL), increases hospitalizations and is associated with speech and eating difficulties, decreased employment, social withdrawal, stigmatization, and amplified emotional distress. In this podcast, hear from a patient who suffered with TD for years before diagnose, and discuss how to identify and support patients with TD.

Learning Objectives
Upon completion of this activity, learners should be able to:

• Identify the early manifestations of tardive dyskinesia (TD) in patients on antipsychotic therapy
• Recognize the burden associated with untreated TD and the consequences of delayed diagnosis

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).

Summary of Individual Disclosures
Angela Golden has disclosed the following financial relationships:

• Consultant: SetPoint (obesity), WW (obesity)
• Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)
• Speaker: Currax (obesity), Novo Nordisk (obesity)
• Receipt of Royalty: Amazon (fiction books), Springer (obesity book)

Greg Mattingly has disclosed the following financial relationship:

• Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, Teva
• Speaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris Pharma
• Contracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva
• All his disclosures are related to mental health

Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.